Linked Life Data

10190231

Source:http://linkedlifedata.com/resource/pubmed/id/10190231

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1999-7-21
pubmed:abstractText
The pharmacoeconomic evaluation of atypical antipsychotics for patients with schizophrenia requires focus on both clinical and quality of life effects and impact on the cost of medical resources. The results of pharmacoeconomic studies help clinicians and health care decision makers identify treatments that provide the most benefit to patients at the most acceptable cost. The cost-effectiveness of antipsychotic drugs has been evaluated using noncontrolled, mirrorimage (i.e. retrospective/prospective) cohort study designs; clinical decision analysis models; and randomized clinical trials. The current pharmacoeconomic evidence suggests that clozapine is a cost-effective therapy for neuroleptic-refractory schizophrenia and that although olanzapine and risperidone therapy may be cost neutral, they improve outcome in patients treated for schizophrenia.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0920-9964
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
35 Suppl
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
S101-9
pubmed:dateRevised
2010-9-2
pubmed:meshHeading
pubmed:year
1999
pubmed:articleTitle
Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia.
pubmed:affiliation
MEDTAP International, Inc., Bethesda, MD 20814, USA. revicki@medtap.com
pubmed:publicationType
Journal Article, Review